FDA approves kallikrein inhibitor to treat hereditary angioedema.
Thompson
Cheryl A
CA
D000293:Adolescent; D000328:Adult; D000368:Aged; D054179:Angioedemas, Hereditary / Q000188:drug therapy*; D017277:Drug Approval; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
D004791:Enzyme Inhibitors; D010455:Peptides; C511194:ecallantide; D007610:Kallikreins